Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS study of guselkumab for subclinical musculoskeletal inflammation in psoriasis
ChiCTR2500103942Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in psoriasis, sponsored by West China Hospital of Sichuan University. Primary endpoint: Musculoskeletal Power Doppler Ultrasound Composite Score. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2500103942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103942.